Overview

A Single-Arm, Phase b Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC

Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This study is a phase Ib, single-center, single-arm exploratory clinical study designed to evaluate the safety and efficacy of Golidocitinib in combination with anti-PD-1 monoclonal antibody in locally advanced or metastatic NSCLC treated with anti-PD-1 in combination with or without platinum-containing chemotherapy regimens.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Chest Hospital